National Graphite Corp. 是一家勘探公司,从事黄金、白银及相关矿物的勘探。公司总部位于北莱茵-威斯特法伦州杜塞尔多夫。该公司于2009年6月30日上市。该公司正在推进一种候选药物elafin的商业化开发,用于治疗术后炎症并发症。Elafin是一种人同源蛋白。公司主要在德国运营,与处于临床阶段的公司合作,开发用于治疗各种疾病、罕见病以及未满足医疗需求疾病的新型生物实体或新型治疗平台。Biotech Development Corp. 是该公司的子公司。截至2015年2月28日,该公司尚未产生任何收入。
NGRC stock price ended at $0.03 on 星期四, after rising 50.00%
On the latest trading day May 14, 2026, the stock price of NGRC rose by 50.00%, climbing from $0.03 to $0.03. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.03 and a high of $0.03. Notably, trading volume dropped by 833 shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 1.0K shares were traded, equating to a market value of approximately $4.6M.